Breaking News Instant updates and real-time market news.

RARE

Ultragenyx

$76.82

0.06 (0.08%)

11:50
02/17/17
02/17
11:50
02/17/17
11:50

Ultragenyx assumed with an Outperform at Wedbush

Wedbush analyst David Nierengarten assumed coverage of Ultragenyx Pharmaceutical with an Outperform rating and lowered his price target for the shares to $88 from $92. With six late stage programs, the analyst is "upbeat" on Ultragenyx's evolution into a mature stand-alone rare disease company with near-term commercial opportunity."

  • 24

    Feb

RARE Ultragenyx
$76.82

0.06 (0.08%)

10/18/16
JEFF
10/18/16
NO CHANGE
JEFF
Jefferies sees 'attractive buying opportunities' in Biotech
The Jefferies Biotechnology team sees "attractive buying opportunities" amidst the pre-election weakness. While volatility will likely continue into the election, valuation multiples are near-historic lows and policy concerns, while valid, are likely overstated, the analysts tell investors in a research note. They recommend using the weakness to buy select names ahead of a potential improvement in sentiment. Jefferies likes Gilead (GILD) and Celgene (CELG) among large-caps, The Medicines Co. (MDCO), Alkermes (ALKS) and Vertex (VRTX) among mid-caps, and Alder Biopharmaceuticals (ALDR), Cempra (CEMP), Ultragenyx (RARE) and Immunomedics (IMMU) among small-caps.
11/01/16
PIPR
11/01/16
NO CHANGE
Target $82
PIPR
Overweight
Ultragenyx risk/reward favorable after pullback, says Piper Jaffray
Piper Jaffray analyst Steven Breazzano says Ultragenyx's risk/reward profile is favorable following the recent pullback in the shares. The analyst recommends buying the stock based on the blockbuster potential of KRN23 in adult and pediatric X-linked hypophosphatemia patients. After taking a closer look at Ultragenyx's UX007 Phase 2 program for both fatty acid oxidation disorders and Glut1 deficiency syndrome, the analyst sees a greater than 50% chance of success in both. He notes the program would represent "meaningful upside" to his model. He reiterates an Overweight rating on Ultragenyx with an $82 price target.
11/08/16
ADAM
11/08/16
NO CHANGE
Target $108
ADAM
Buy
Ultragenyx price target lowered to $108 from $120 at Canaccord
Canaccord analyst Arlinda Lee lowered her price target on Ultragenyx to $108 from $120 due to an expected increase in R&D spending after the company reported pipeline progress on four clinical candidates and said it expects to file for U.S. KRN23 pediatric approval earlier than expected in the second half of 2017. Lee reiterated her Buy rating on Ultragenyx shares as she expects regulatory approvals in 2017, while also citing its attractive pipeline.
11/14/16
SBSH
11/14/16
DOWNGRADE
Target $64
SBSH
Sell
Ultragenyx downgraded to Sell from Neutral at Citi
Citi analyst Yigal Nochomovitz downgraded Ultragenyx to Sell after removing Ace-ER sales from his model "in the absence of stronger data." The analyst lowered his price target for the shares to $64 from $66.

TODAY'S FREE FLY STORIES

UHT

Universal Health Realty

$75.28

1.705 (2.32%)

11:45
12/13/17
12/13
11:45
12/13/17
11:45
Conference/Events
Universal Health Realty management to meet with Jefferies »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

11:40
12/13/17
12/13
11:40
12/13/17
11:40
General news
Bund/T-note spread widening remains intact »

Bund/T-note spread…

CERN

Cerner

$70.36

0.23 (0.33%)

11:39
12/13/17
12/13
11:39
12/13/17
11:39
Periodicals
VA Secretary says contract with Cerner held up by questions, Politico reports »

Veterans Affairs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CACC

Credit Acceptance

$326.25

3.97 (1.23%)

11:34
12/13/17
12/13
11:34
12/13/17
11:34
Hot Stocks
PlainSite says Credit Acceptance disclosures belie 'deeply flawed' model »

In a "Reality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSGP

CoStar Group

$287.83

-2.67 (-0.92%)

11:33
12/13/17
12/13
11:33
12/13/17
11:33
Conference/Events
CoStar Group management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 15

    Dec

  • 26

    Feb

ROG

Rogers Corporation

$158.59

1.4 (0.89%)

11:30
12/13/17
12/13
11:30
12/13/17
11:30
Conference/Events
Rogers Corporation management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 15

    Dec

11:30
12/13/17
12/13
11:30
12/13/17
11:30
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

ROG

Rogers Corporation

$158.89

1.7 (1.08%)

11:29
12/13/17
12/13
11:29
12/13/17
11:29
Conference/Events
Rogers Corporation management to meet with B. Riley FBR »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 15

    Dec

HDP

Hortonworks

$19.76

0.18 (0.92%)

11:25
12/13/17
12/13
11:25
12/13/17
11:25
Conference/Events
Hortonworks management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

  • 26

    Feb

CACC

Credit Acceptance

$326.25

3.97 (1.23%)

11:20
12/13/17
12/13
11:20
12/13/17
11:20
Hot Stocks
Credit Acceptance moves lower following short report from PlainSite »

Shares of Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
12/13/17
12/13
11:17
12/13/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
12/13/17
12/13
11:16
12/13/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RL

Ralph Lauren

$96.15

-3.99 (-3.98%)

11:13
12/13/17
12/13
11:13
12/13/17
11:13
Hot Stocks
Ralph Lauren falls after Bofa/Merrill downgrade cites 'dimming' margin story »

Shares of Ralph Lauren…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.58

0.555 (0.91%)

11:10
12/13/17
12/13
11:10
12/13/17
11:10
Hot Stocks
Target: Shipt to continue to run business independently post-acquisition »

Shipt will be a wholly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$63.48

0.41 (0.65%)

, T

AT&T

$37.75

-0.35 (-0.92%)

11:10
12/13/17
12/13
11:10
12/13/17
11:10
Hot Stocks
Cable, telecom stocks dip as T-Mobile plans to bring 'un-carrier' to TV »

T-Mobile (TMUS) is…

TMUS

T-Mobile

$63.48

0.41 (0.65%)

T

AT&T

$37.75

-0.35 (-0.92%)

ROKU

Roku

$46.95

-1.03 (-2.15%)

CMCSA

Comcast

$39.51

1.07 (2.78%)

CMCSK

Comcast

CHTR

Charter

$329.99

-1.5 (-0.45%)

VZ

Verizon

$52.82

-0.375 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

  • 13

    Dec

LITE

Lumentum

$51.75

-1.75 (-3.27%)

, FNSR

Finisar

$19.30

-0.51 (-2.57%)

11:09
12/13/17
12/13
11:09
12/13/17
11:09
Recommendations
Lumentum, Finisar, Apple analyst commentary  »

Apple's investment…

LITE

Lumentum

$51.75

-1.75 (-3.27%)

FNSR

Finisar

$19.30

-0.51 (-2.57%)

AAPL

Apple

$171.70

-0.97 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$185.73

-0.49 (-0.26%)

11:09
12/13/17
12/13
11:09
12/13/17
11:09
Periodicals
Netflix executive fired over Masterson assault comments, Page Six says »

Netflix director of kids…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.64

0.62 (1.02%)

11:06
12/13/17
12/13
11:06
12/13/17
11:06
Technical Analysis
Technical View: Target spikes after acquiring Shipt for $550M »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.70

0.68 (1.11%)

11:02
12/13/17
12/13
11:02
12/13/17
11:02
Hot Stocks
Breaking Hot Stocks news story on Target »

Target to bring same-day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.69

0.67 (1.10%)

11:01
12/13/17
12/13
11:01
12/13/17
11:01
Hot Stocks
Breaking Hot Stocks news story on Target »

Target: Same-day delivery…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.72

0.71 (1.16%)

11:01
12/13/17
12/13
11:01
12/13/17
11:01
Hot Stocks
Target to buy same-day delivery platform Shipt for $550M in cash »

Target announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AYI

Acuity Brands

$165.44

-8.79 (-5.05%)

10:59
12/13/17
12/13
10:59
12/13/17
10:59
Technical Analysis
Technical View: Acuity Brands tumbles, levels to watch »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 09

    Jan

10:52
12/13/17
12/13
10:52
12/13/17
10:52
Conference/Events
Jefferies software/cybersecurity analyst holds analyst/industry conference call »

Analyst DiFucci, along…

VIPS

Vipshop

$8.30

0.115 (1.41%)

10:50
12/13/17
12/13
10:50
12/13/17
10:50
Options
Opening action in Vipshop far upside calls »

Opening action in Vipshop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$84.72

0.2568 (0.30%)

10:45
12/13/17
12/13
10:45
12/13/17
10:45
Periodicals
Novartis' Sandoz generics unit may sell or close some products, Reuters reports »

Novartis is in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 17

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.